Business Description
Vera Therapeutics Inc
NAICS : 325412
SIC : 2834
8000 Marina Boulevard, Suite 120, Brisbane, CA, USA, 94005
Description
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 11.81 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | -0.29 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 0 | |||||
Beneish M-Score | 0 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 83.85 | |||||
9-Day RSI | 78.49 | |||||
14-Day RSI | 73.29 | |||||
6-1 Month Momentum % | -23.48 | |||||
12-1 Month Momentum % | -15.21 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.9 | |||||
Quick Ratio | 7.9 | |||||
Cash Ratio | 7.56 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -78 | |||||
ROA % | -45.96 | |||||
ROIC % | -1415.19 | |||||
ROC (Joel Greenblatt) % | -1324.5 | |||||
ROCE % | -49.81 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 4.1 | |||||
Price-to-Tangible-Book | 4.09 | |||||
EV-to-EBIT | -9.65 | |||||
EV-to-EBITDA | -9.68 | |||||
EV-to-FCF | -15.13 | |||||
Price-to-Net-Current-Asset-Value | 4.33 | |||||
Price-to-Net-Cash | 4.57 | |||||
Earnings Yield (Greenblatt) % | -10.36 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:VERA
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0 | ||
EPS (TTM) ($) | -2.19 | ||
Beta | 0 | ||
Volatility % | 110.26 | ||
14-Day RSI | 73.29 | ||
14-Day ATR ($) | 1.339304 | ||
20-Day SMA ($) | 17.518 | ||
12-1 Month Momentum % | -15.21 | ||
52-Week Range ($) | 12.285 - 37.11 | ||
Shares Outstanding (Mil) | 27.14 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Vera Therapeutics Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |